Intravascular ultrasound developer Endosonics saw revenues jumpsharply for its second quarter (end-June), thanks to increasingdemand in U.S. and global markets. The Pleasanton, CA, company'srevenues for the quarter leaped 234% to $4 million, compared
Intravascular ultrasound developer Endosonics saw revenues jumpsharply for its second quarter (end-June), thanks to increasingdemand in U.S. and global markets. The Pleasanton, CA, company'srevenues for the quarter leaped 234% to $4 million, compared to$1.2 million in sales in the same period a year ago.
Despite the revenue growth, Endosonics continues to post losses.The company had a net loss for the quarter of $3.3 million, includinga non-cash expense of $500,000 to complete its 1993 acquisitionof its CardioVascular Dynamics subsidiary. Endosonics had a netloss of $3.2 million in the second quarter of 1994.
Endosonics said its revenue increase was due to overall growthin the market for intracoronary ultrasound products and increasedsales from its marketing and distribution relationship with Cordis(SCAN 9/14/94). CVD has also seen increased sales of its specializedcatheters.
Endosonics also reported last week that CVD received a $750,000payment from its Japanese distributor, Fukuda Denshi, in returnfor Japanese distribution rights to several new CVD products forperipheral vascular, neurovascular and nonvascular applications.
Emerging PET/CT Agent Shows Promise in Detecting PCa Recurrence in Patients with Low PSA Levels
February 13th 202518F-DCFPyL facilitated detection of recurrent prostate cancer in 51 percent of patients with PSA levels ranging between 0.2 to 0.5 ng/ml, according to new research presented at the American Society of Clinical Oncology Genitourinary Cancers (ASCO-GU) Symposium.
Emerging MRI Scoring System May Help Predict Recurrent and Metastatic Hepatocellular Carcinoma
February 12th 2025Preoperative use of the scoring system for gadoxetic acid-enhanced MRI demonstrated an average AUC of 85 percent and average specificity of 89 percent in external validation cohorts for pathologic features of hepatocellular carcinoma.
Key Chest CT Parameters for Body Composition May be Prognostic for Patients with Resectable NSCLC
February 11th 2025A high intermuscular adipose index has a 49 percent increased likelihood of being associated with lower overall survival in patients with resectable non-small cell lung cancer (NSCLC), according to new research.